During the visit they were able to see first-hand the international contribution that VIVEbiotech makes to the treatment of diseases of genetic origin by producing and developing lentiviral vectors.

They were received by Gurutz Linazasoro, CEO of VIVEbiotech, José Manuel Franco, COO, Juan Carlos Ramírez, CSO/CTO, Natalia Elizalde, Business Development Director, and Maider Goyena, CFO of VIVEbiotech.

VIVEbiotech is the only state company that produces lentiviral vectors for clinical trials of diseases of genetic origin, such as rare diseases, and the only one internationally developing a non-integrative stable lentiviral vector (LENTISOMA).

Read the news here.